SYRA — Syra Health Income Statement
0.000.00%
Last trade - 00:00- $0.70m
- -$1.54m
- $7.98m
Annual income statement for Syra Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.41 | 5.62 | 5.52 | 7.98 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0.43 | 1.06 | 1.41 | 1.65 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 0.004 | 1.41 | 7.71 | 8.4 | 11.7 |
| Operating Profit | -0.004 | -0.003 | -2.09 | -2.89 | -3.76 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.004 | -0.003 | -2.12 | -2.94 | -3.76 |
| Net Income After Taxes | -0.004 | -0.003 | -2.12 | -2.94 | -3.76 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.004 | -0.003 | -2.12 | -2.94 | -3.76 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.004 | -0.003 | -2.12 | -2.94 | -3.76 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.001 | -0.001 | -0.354 | -0.602 | -0.498 |
| Dividends per Share |